The European life sciences industry has a long history. Many of the major players trace their roots to before the war, and often began as agricultural or chemical companies. LSIPR takes a look at the leading jurisdictions.
In the past year or so, life sciences companies have outperformed the stock exchange significantly. Though it would be foolish to call this a boom time for the industry, investors know that there is money to be made in developing innovative biotech solutions.
Countries that have not been traditional life sciences powerhouses are wising up, and the next great success story seems as likely to be from India as from Europe. In this context, the traditional powerhouses of the European life sciences industry will need to be smart, while national and regional governments have to think carefully about how to keep them competitive on the global stage.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Bayer, biotechnology, pharmaceuticals, Astra